市場調査レポート
商品コード
1159431
経鼻ドラッグデリバリーの世界市場(2022年~2028年)Nasal Drug Delivery Market 2022-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
経鼻ドラッグデリバリーの世界市場(2022年~2028年) |
出版日: 2022年10月21日
発行: Orion Market Research
ページ情報: 英文 140 Pages
納期: 2~3営業日
|
世界の経鼻ドラッグデリバリーの市場規模は、予測期間中に5.5%のCAGRで成長すると予測されています。当市場を牽引する主な要因には、喘息と慢性閉塞性肺疾患(COPD)の有病率の上昇などがあります。
当レポートでは、世界の経鼻ドラッグデリバリー市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、セグメント別、地域別の市場分析、主要企業のプロファイルなど、体系的な情報を提供しています。
Global Nasal Drug Delivery Market Size, Share & Trends Analysis Report by Dosage Form (Gels, Sprays, Drops and Liquids, and Others), by Containers (Non-Pressurized Containers, and Pressurized Containers), by Therapeutic Application (Rhinitis, Nasal Congestion, Asthma, and Others) and by End-User (Hospitals, and Home Health Care) Forecast Period (2022-2028)
The global nasal drug delivery market is anticipated to grow at a substantial CAGR of 5.5% during the forecast period. The rising prevalence of Asthma and chronic obstructive pulmonary disease (COPD) are factors that are driving the market growth. Increasing patients pool of asthma and COPD across the globe are factors that increase the demand for nasal drugs for the treatment of diseases in the market. For instance, the report published by the Asthma and Allergy Foundation of America (AAFA), in May 2021, stated that approximately 25 million people alone in the US are suffering from asthma that is equal to 1 in 13 people aged 18 and older are living with asthma. Asthma rates are highest in black adults in the US in comparison with white adults.
The nasal drug delivery is segmented on the basis of dosage form, containers, therapeutic application, and end-user. Based on dosage form, the market is segmented into gels, sprays, drops and liquids, and others. On the basis of containers, the market is sub-divided into non-pressurized containers and pressurized containers. On the basis of therapeutic application, the market is sub-divided rhinitis, nasal congestion, asthma, and others. Furthermore, based on end-user, the market is sub-classified into hospitals and home health care. Among the end-user segment hospital segments are holding a prominent share owing to an increased number of patients pool administered in hospitals for the treatment of various diseases such as asthma, COPD, and others.
Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds a prominent share in the market owing to the increasing prevalence of asthma and chronic obstructive pulmonary disease and the rising adoption of technology-based treatment at procedures at an early stage. Furthermore, several technological advancements and growing product launches and innovations by key industry players in the market. For instance, in April 2019, Aptar Pharma, a new Bidose nasal spray device was approved by the US Food Drug Administration (FDA), for breakthrough therapy in the field of depression. This new Bidose liquid system intuitive and easy-to-use device with 360° functionality and precise spray characteristics and provides two-shot nasal drug delivery. Moreover, the growing number of individuals affected with asthma is such factor that is contributing to the North American region's market growth.
The competitive landscape includes key strategies of leading players, recent developments, and key company analysis. The major players that contribute to the growth of the market include 3M Co., APTARGROUP INC., AstraZeneca, Becton Dickinson and Co., Johnson & Johnson Service Inc., Merck KGaA, Novartis International AG, and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2021, Nanoform Finland Plc and Herantis Pharma Plc entered into an agreement for the formulation of Proof of Concept projects (PoCs) that aims to enhance nasal drug delivery to the brain. Both the companies in collaboration stated to develop a formulation that increases penetration into the brain via the nasal drug delivery route for CDNF.
Research Methodology
The market study of the global nasal drug delivery market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers: